Canada · Delayed Price · Currency is CAD Avicanna Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed strong financial improvements in 2025, including higher gross margins, reduced net loss, and positive adjusted EBITDA in Q4. All board nominees and proposals, including the incentive plan, were approved, and strategic focus remains on Canadian, U.S., and international expansion.
-
The company is advancing a diversified, evidence-based cannabinoid platform with four business divisions, a robust pharmaceutical pipeline, and proprietary IP. It is expanding internationally, leveraging Canadian success, and expects U.S. regulatory changes to unlock new growth and partnerships.
Fiscal Year 2025
-
Revenue reached CAD 25.5 million with a 53% gross margin and near break-even adjusted EBITDA. Expanded to 24 international markets, launched new proprietary drug delivery technologies, and improved operational efficiency. Positioned for further growth and U.S. market entry in 2026.
-
Expanded product portfolio and international reach, with new patented technologies and clinical studies supporting growth. Improved financials and operational efficiency position the company for scale-up and profitability in 2026, with a focus on IP, medical platforms, and global markets.
Fiscal Year 2024
-
Record 2024 revenue and gross profit were driven by MyMedi platform growth and improved margins, with a narrowed EBITDA loss and reduced debt. The company expects profitability in 2025, continued Canadian leadership, and international expansion, especially in Europe and South America.